Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Verrica Pharmaceuticals (VRCA) Income from Continuing Operations (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of Income from Continuing Operations data on record, last reported at 8301000.0 in Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 38.76% year-over-year to 8301000.0; the TTM value through Dec 2025 reached 18998000.0, up 74.3%, while the annual FY2025 figure was 18998000.0, 74.3% up from the prior year.
  • Income from Continuing Operations reached 8301000.0 in Q4 2025 per VRCA's latest filing, down from 308000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 1513000.0 in Q3 2022 and bottomed at 24753000.0 in Q3 2023.
  • Average Income from Continuing Operations over 5 years is 10898200.0, with a median of 10081500.0 recorded in 2022.
  • Peak YoY movement for Income from Continuing Operations: soared 111.79% in 2022, then crashed 1736.02% in 2023.
  • A 5-year view of Income from Continuing Operations shows it stood at 9540000.0 in 2021, then skyrocketed by 38.49% to 5868000.0 in 2022, then crashed by 320.06% to 24649000.0 in 2023, then skyrocketed by 45.01% to 13554000.0 in 2024, then soared by 38.76% to 8301000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 8301000.0 in Q4 2025, 308000.0 in Q3 2025, and 393000.0 in Q2 2025.